Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Introduction
00:00 • 3min
The Importance of Pipeline Adjustments
02:57 • 2min
The Potential of CAR T Therapies in Immunology
05:10 • 2min
The Outlook for M&As
07:11 • 3min
The Future of Platform Acquisitions
10:02 • 2min
How to Reconcile a Bid Ask When Running a Platform Based Company
11:51 • 3min
How to See Value While Keeping the Platform
15:04 • 2min
The John Merigonori Factor to Success
17:16 • 2min
Vedanta Biosciences: A New Approach to Microbiome Therapy
18:57 • 4min
The Microbiome Drugs Market at Cubist
22:57 • 3min
Morphology Data: The Challenges and Opportunities
26:14 • 3min
The Oral Opportunity for Inflammatory Bowel Disease
29:22 • 5min
The Importance of Preclinical Data in Oral Drugs
34:22 • 2min
The Importance of Consistency in Drug Development
36:42 • 2min
Praveen: Announcing Good Data Raises Funds
38:23 • 2min
The Positive Early Data and Extra Hepatic RNAi From Arrowhead Pharmaceuticals and Its Partners Regeneron and Al Mylam
39:54 • 2min
The Role of RNA I in the Development of Tritical Therapy
42:08 • 2min
RNA Eyes for Spinal Muscular Atrophy
44:12 • 2min
The Importance of OCT Images in Ophthalmology
45:47 • 2min
The Role of Biomerin in the Treatment of Visual Acuity
48:04 • 5min
FDA's Frustration With Feedback From Companies
52:52 • 2min
The Importance of Persistence in Innovation
54:29 • 2min
Bristol Myers CEO Steps Down
56:30 • 3min